Despite increased evidence supporting routine evaluation and screening cases of HER2 amplification and respective use of targeted therapy in G&CRC, advances in this field have not been as readily recognized and adopted by healthcare professionals (HCPs) and the wider community [10]. The gene discussed is ERBB2; the disease is colorectal carcinoma.